ublituximab-xiyl bulk supplier for pharma manufacturers

Ublituximab-Xiyl 150 mg/6 mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 150 mg/6 mL

Reference Brands: Briumvi (USA/EU)

Category: Neurology

ublituximab-xiyl is a CD20-directed monoclonal antibody that targets B-cells responsible for nerve damage in multiple sclerosis. It helps reduce relapses and slow disability progression in adults with relapsing forms of MS. Administered as an intravenous infusion, it offers a targeted approach with fewer infusion sessions compared to some other MS therapies.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Ublituximab-Xiyl — third party manufacturing & bulk supply

Ublituximab-Xiyl 150 mg/6 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ublituximab-Xiyl is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ublituximab-Xiyl listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ublituximab-Xiyl →

Back to Listing

Frequently Asked Questions

ublituximab-xiyl is listed as Injection in 150 mg/6 mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

ublituximab-xiyl is referenced against Briumvi (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.